Cargando…

Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity

Asparagine-linked (N-linked) glycosylation is ubiquitous and can stabilize immune inhibitory PD-1 protein. Reducing N-linked glycosylation of PD-1 may decrease PD-1 expression and relieve its inhibitory effects on CAR-T cells. Considering that the codon of Asparagine is aac or aat, we wondered if th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xiaojuan, Zhang, Daiqun, Li, Feng, Zhang, Zhen, Wang, Shumin, Xuan, Yujing, Ping, Yu, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884797/ https://www.ncbi.nlm.nih.gov/pubmed/31783892 http://dx.doi.org/10.1186/s13045-019-0831-5

Ejemplares similares

PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020)

Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models
por: Xuan, Yujing, et al.
Publicado: (2021)

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway
por: Ji, Feng, et al.
Publicado: (2021)

The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity
por: Ahmad, S M, et al.
Publicado: (2014)

Loss of Spike N370 glycosylation as an important evolutionary event for the enhanced infectivity of SARS-CoV-2
por: Zhang, Shuyuan, et al.
Publicado: (2022)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
por: Xu, Da-Lai, et al.
Publicado: (2022)

Chrysin targets myeloid‐derived suppressor cells and enhances tumour response to anti‐PD‐1 immunotherapy
por: Li, Yinan, et al.
Publicado: (2022)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions
por: Zhang, Li, et al.
Publicado: (2020)

Exosomes: Promising biomarkers and targets for cancer
por: Fang, Zhen, et al.
Publicado: (2022)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
por: Zhang, Qiqi, et al.
Publicado: (2022)

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia
por: Wang, Guoling, et al.
Publicado: (2021)

O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an “O-Follow-N” rule
por: Tian, Wenmin, et al.
Publicado: (2021)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
por: Heard, Amanda, et al.
Publicado: (2022)

Intrinsic PD‐L1 promotes antitumor activity of CD8(+) cytotoxic T lymphocytes via in cis interaction with CD80
por: Ding, Yuming, et al.
Publicado: (2022)

When glycosylated hemoglobin is a true roller coaster
por: Peixoto, Fabiana Ribeiro, et al.
Publicado: (2018)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2021)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Motor-Car Cots
por: Kirkaldy, D. D.
Publicado: (1914)

CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma
por: Deng, Wenhai, et al.
Publicado: (2021)

IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
por: Dong, E, et al.
Publicado: (2021)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
por: Wu, Jianghua, et al.
Publicado: (2023)

Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19
por: Mitsuyama, Yumi, et al.
Publicado: (2021)

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro
por: Zhang, Shuo, et al.
Publicado: (2017)

Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells
por: Zheng, Yifeng, et al.
Publicado: (2023)

Enhancing targeted transgene knock‐in by donor recruitment
por: Jiao, Guanyi, et al.
Publicado: (2021)

Correction: PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
Publicado: (2022)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

In situ forming injectable MSC-loaded GelMA hydrogels combined with PD for vascularized sweat gland regeneration
por: Jirigala, Enhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ijpbc7f4j1gb9avio1uijnbb15